Reference · Compound library

Every FDA-approved GLP-1,
modeled correctly.

Protokol Lab ships pharmacokinetic defaults for every FDA-approved GLP-1 receptor agonist. Each built-in compound carries published peer-reviewed PK values so dose curves are accurate from the first injection — not a generic decay line.

Built-in compounds

CompoundBrand namesHalf-life (t½)RouteTypical interval
TirzepatideMounjaro, Zepbound~5 daysSub-QWeekly
SemaglutideOzempic, Wegovy~7 daysSub-QWeekly
Semaglutide (oral)Rybelsus~7 daysOralDaily
LiraglutideSaxenda, Victoza~13 hoursSub-QDaily
DulaglutideTrulicity~5 daysSub-QWeekly

Compounded versions

Compounded tirzepatide and compounded semaglutide from a licensed compounding pharmacy contain the same active peptides as the brand-name versions. Use the built-in Tirzepatide or Semaglutide preset — the half-life, kinetic shape, and dose-to-active-level math are identical. Record your prescribed mg per injection, not the pen or vial label.

Custom compounds

For any compound outside the FDA-approved list — for example, a substance prescribed under a clinical trial, an investigational formulation, or a compounded mix with non-standard concentrations — users can add a custom compound by entering a name and a half-life.

Protokol Lab does not publish pharmacokinetic defaults for compounds that are not FDA-approved. Users supply their own values and assume full responsibility for the accuracy of those values and for the legality of any substance they choose to track. Protokol Lab does not sell, ship, distribute, refer users to, or endorse any pharmacy, telehealth provider, or compounding facility for any substance.

How Protokol Lab models these

Every dose is modeled with the Bateman equation — the standard two-compartment pharmacokinetic model for extravascular absorption. For subcutaneous peptides, the kinetic shape is a rise over a few hours (absorption rate ka) followed by first-order elimination at the compound's half-life.

When you stack multiple doses of the same compound, or run multiple compounds simultaneously, curves are summed correctly so the active level at any point in time reflects the full schedule — not just the most recent injection.

Supported kinetic profiles

  • Bolus — instant peak, exponential decay. IV-like, or anything with near-immediate peak.
  • Sub-Q — rises over a few hours, then decays. Default for self-injected peptides and GLP-1s.
  • Depot — slow release, lower peak, long tail. Long-acting weekly formulations and oil-based depots.

Citations

  • Urva S, et al. "Effects of renal impairment on the pharmacokinetics of the dual GIP and GLP-1 receptor agonist tirzepatide." Clinical Pharmacokinetics (2021). Tirzepatide t½ ≈ 5 days.
  • Lau J, et al. "Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide." Journal of Medicinal Chemistry (2015). Semaglutide t½ ≈ 7 days.
  • Agersø H, et al. "The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative." Diabetologia (2002). Liraglutide t½ ≈ 13 hours.
  • Barrington P, et al. "Dulaglutide pharmacokinetics and pharmacodynamics." Diabetes, Obesity and Metabolism (2011). Dulaglutide t½ ≈ 5 days.
Protokol Lab is an organizational and mathematical modeling tool. It is not a medical device and does not provide medical advice, diagnosis, treatment, or dosing recommendations. Pharmacokinetic curves are mathematical estimates for informational purposes only and do not reflect real-time biological or serum diagnostics. Consult a licensed medical professional before making any decision about your medication or health.
Sign up free